ATTR-ACT: Tafamidis improves quality of life in transthyretin amyloid cardiomyopathy

ATTR-ACT: Tafamidis improves quality of life in transthyretin amyloid cardiomyopathy

PHILADELPHIA — Tafamidis was associated improvements in a variety metrics quality ATTR-ACT: Tafamidis improves in patients transthyretin cardiomyopathy, in main ATTR-ACT trial, was associated reduced for all-cause mortality hospitalization at 30 months placebo. Tafamidis tafamidis meglumine (Vyndaqel,” Mazen staff cardiologist in Failure Transplantation Medicine in Arnold Miller Family & Vascular Institute, said a presentation at Failure Society America Meeting. “A key endpoint was that in health care-related quality was less in tafamidis arm than in placebo arm.

Transthyretin amyloid cardiomyopathy is a rare inherited and slowly progressive cardiac disease, in which a protein-based infiltrate deposits in tissues as beta-pleated sheets. The disease is characterized by an abnormal buildup of deposits of a mutant and wild-type transthyretin (TTR) protein in the heart called TTR amyloid fibrils in the body's organs and tissues. This leads to diastolic dysfunction from restrictive cardiomyopathy and eventual heart failure. In amyloid cardiomyopathy the U. S. , the most common mutation (V122I) is seen predominantly among individuals of African descent.  There are three types of transthyretin amyloid cardiomyopathy: light-chain amyloidosis, mutant transthyretin amyloidosis, and wild-type transthyretin amyloidosis. All three forms of transthyretin amyloid cardiomyopathy are progressive and fatal. For patients with wild-type transthyretin amyloidosis cardiomyopathy and mutant transthyretin amyloidosis cardiomyopathy, symptoms usually manifest later in life (after the age of 50).

*** The operating environment for global increasingly getting complex. This has left catch-up with constantly emerging strategies. There growing demand for inclusion best-consulting services Transthyretin Amyloid Cardiomyopathy sync with organization’s strategy. The transformation Familial Amyloid Cardiomyopathy functional areas can be integrated into every At Coherent Market market valuation, potential drivers challenges, competition situation, which empower stakeholders to obtain clear understanding this.

Comments

Popular posts from this blog

Deaths to heart related conditions rising in the US

Here’s the US military dog that helped take down ISIS leader Baghdadi

Springfield hospital adds new heart surgery procedure